Depomed, Inc.has announced that it has entered into a definitive agreement to acquire the U.S. rights to the Nucynta franchise...
A Phase III study suggests Nucynta ER (tapentadol) tablets, from J&J Janssen, were significantly more effective than placebo in providing...
Depomed, Inc. announced that it has closed the acquisition of the U.S. rights to the Nucynta franchise from Janssen Pharmaceuticals,...
Horizon Pharma plc announced a proposal to acquire all outstanding shares of Depomed, Inc. for approximately $3.0 billion. DepoMed products...